Biotech company Mission Therapeutics has raised $13.3 million to progress the clinical development of its lead candidate for the treatment of Parkinson’s disease.  The lead candidate MTX35 works by inhibiting USP30, a mitochondrial de-ubiquitylating enzyme (DUB), increasing mitochondrial ubiquitylation and promoting appropriate mitophagy. This is the essential process cells use to rid themselves of dysfunctional […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!